Previous close | 10,742.00 |
Open | 10,756.00 |
Bid | 10,718.00 x 0 |
Ask | 10,720.00 x 0 |
Day's range | 10,714.04 - 10,780.00 |
52-week range | 9,461.00 - 12,392.00 |
Volume | |
Avg. volume | 2,930,198 |
Market cap | 166.158B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 35.49 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.28 (2.12%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.